These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32997475)

  • 1. Health aspects of exposure to emissions from burning coal of high beryllium content: interactions with the immune system.
    Petanová J; Bencko V
    Cent Eur J Public Health; 2020 Sep; 28(3):198-201. PubMed ID: 32997475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.
    McCleskey TM; Buchner V; Field RW; Scott BL
    Rev Environ Health; 2009; 24(2):75-115. PubMed ID: 19658317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of the humoral and cellular immunological response in berylliosis].
    Vasil'eva EV; Ermakova NG
    Gig Tr Prof Zabol; 1980 Aug; (8):50-1. PubMed ID: 7399295
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunologic Effects of Beryllium Exposure.
    Fontenot AP
    Ann Am Thorac Soc; 2018 Apr; 15(Suppl 2):S81-S85. PubMed ID: 29676647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hygienic and toxicological aspects of occupational and environmental exposure to beryllium.
    Bencko V; Vasil'eva EV
    J Hyg Epidemiol Microbiol Immunol; 1983; 27(4):403-17. PubMed ID: 6663073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic beryllium disease: a model interaction between innate and acquired immunity.
    Sawyer RT; Maier LA; Kittle LA; Newman LS
    Int Immunopharmacol; 2002 Feb; 2(2-3):249-61. PubMed ID: 11811929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
    Fontenot AP; Maier LA
    Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
    Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
    Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
    Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
    Judd NL; Griffith WC; Takaro T; Faustman EM
    Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological aspects of exposure to emissions from burning coal of high beryllium content.
    Bencko V; Vasilieva EV; Symon K
    Environ Res; 1980 Aug; 22(2):439-49. PubMed ID: 6967812
    [No Abstract]   [Full Text] [Related]  

  • 12. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease.
    Fontenot AP; Canavera SJ; Gharavi L; Newman LS; Kotzin BL
    J Clin Invest; 2002 Nov; 110(10):1473-82. PubMed ID: 12438445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic beryllium disease: an updated model interaction between innate and acquired immunity.
    Sawyer RT; Maier LA
    Biometals; 2011 Feb; 24(1):1-17. PubMed ID: 20981472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent chronic beryllium disease in residents surrounding a beryllium facility: patients' information.
    Rossman MD
    Am J Respir Crit Care Med; 2009 Jan; 179(2):173. PubMed ID: 19119155
    [No Abstract]   [Full Text] [Related]  

  • 15. Beryllium exposure: dermal and immunological considerations.
    Day GA; Stefaniak AB; Weston A; Tinkle SS
    Int Arch Occup Environ Health; 2006 Feb; 79(2):161-4. PubMed ID: 16231190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.
    Fontenot AP; Edwards DM; Chou YK; Mack DG; LaTocha D; Vandenbark AA; Burrows GG
    Eur J Immunol; 2006 Apr; 36(4):930-9. PubMed ID: 16552706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beryllium workers--sarcoidosis or chronic beryllium disease.
    Williams WJ
    Sarcoidosis; 1989 Oct; 6 Suppl 1():34-5. PubMed ID: 2623376
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.
    Fontenot AP; Keizer TS; McCleskey M; Mack DG; Meza-Romero R; Huan J; Edwards DM; Chou YK; Vandenbark AA; Scott B; Burrows GG
    J Immunol; 2006 Sep; 177(6):3874-83. PubMed ID: 16951350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic exposure to low concentrations of beryllium on the level of human serum immunoglobulins].
    Chesnokov VA; Belova AA
    Gig Tr Prof Zabol; 1979 Aug; (8):38-40. PubMed ID: 488724
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.
    Fontenot AP; Newman LS; Kotzin BL
    Clin Immunol; 2001 Jul; 100(1):4-14. PubMed ID: 11414740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.